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Aims: Despite a significant increase in using cannabis for medical purposes, current
evidence on its safety in real-world clinical practice is still poorly characterised. By a
case-by-case analysis of spontaneous reports of suspected adverse events (AEs)
collected in Tuscany within the Italian Phytovigilance database, the aim of the
present study was to describe AEs occurred in patients exposed to medical cannabis.
Methods: We evaluated all reports of cannabis-related suspected AEs collected
within the Phytovigilance database up to December 2018. Information regarding
cannabis therapy, patient's demographic and clinical characteristics, concomitant
medications, AE description according to the Medical Dictionary for Regulatory
Activities (MedDRA) classification, AE seriousness and AE outcome, were collected.
The causality assessment was performed following World Health Organisation–
Uppsala Monitoring Centre criteria.
Results: Fifty-three cannabis-related AE reports were analysed. The majority of
patients were females (77.3%), with a mean age of 61.9 years. Thirty-nine (73.6%)
cases were defined as nonserious and the majority of them (86.9%) showed a com-
plete resolution or improvement. Forty-six (86.8%) cases were judged as probably
related to cannabis consumption. The most frequently reported system organ class
was psychiatric and nervous system disorders, and a potential drug–drug interaction
was present in 16 cases.
Conclusion: Cannabis was generally well tolerated and the majority of AEs were mild
and transient. Our analysis highlighted important safety issues for clinical practice, in
particular the need for an accurate prescription monitoring during the titration phase,
particularly in the presence of concomitant medications.
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1 | INTRODUCTION
Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the main
active substances in Cannabis sativa, and have several pharmacological
targets that include both cannabinoid (CB) receptors (CB1 and CB2),
the calcitonin gene-related peptide orphan receptor, the ligand-gated
ion channels of human 5-HT3A receptors, and other additional ionic
channels and enzymes.1,2 The action of THC and CBD on these tar-
gets is responsible for their therapeutic properties, ranging from pain
relief to antiemetic, antiepileptic and anticraving effects.3
Recent evidence shows the positive effects of medical cannabis
use both as first-line treatment and as adjuvant therapy in several clin-
ical conditions, identifying cannabis as a valid therapeutic option. In a
study published by Bellnier and colleagues, the use of cannabis has
led patients with chronic pain to discontinue their opioids, or to
reduce opioids doses by approximately 75%.4 In patients affected by
Dravet syndrome, CBD administration have reduced monthly drop
seizure frequency from baseline by 43.9%, with the occurrence of
mild or moderate adverse events (AEs).5 In a systematic review and
meta-analysis performed to evaluate the efficacy and safety of canna-
binoids in different clinical settings, 79 trials for a total of 6462 partic-
ipants have been included. Compared with placebo, a higher number
of patients treated with cannabinoids have shown: (i) nausea and
vomiting complete response; (ii) greater reduction in numerical rating
scale pain assessment; (iii) greater reduction in the Ashworth spastic-
ity scale. The study has highlighted an increased risk of short-term
AEs with cannabinoids, including those classified as serious.6 Another
study by Nugent and colleagues7 reviewed the benefits of cannabis
preparations for treating chronic pain in adults and the harms of can-
nabis use in chronic pain and general adult populations. Authors per-
formed a systematic review of 27 chronic pain trials, 11 systematic
reviews and 32 primary studies, concluding that cannabis may allevi-
ate neuropathic pain in some patients, but insufficient evidence exists
for other types of chronic pain. They also highlighted that cannabis is
associated with an increased risk for adverse mental health effects.
In studies evaluating the safety of medical cannabis over all indi-
cations, it has been found to be safe and well tolerated,8 and its AEs
have been considered less severe than those of other prescribed
drugs.9 Nevertheless, different suspected AEs have been reported fol-
lowing cannabis consumption, and despite the significant increase in
use, the current evidence on safety of medical cannabis in real-world
clinical practice are is poorly characterised.
Italy legally recognised medical use of cannabis since 2006, when
the Ministry of Health authorised cannabis import from the Nether-
lands. In 2016, Italian production of cannabis was authorised and the
Military Pharmaceutical Chemical Works (Florence) started growing
and processing cannabis in a controlled and standardised setting,
according to Good Manufacturing Practice. Medical cannabis can be
prescribed as magistral preparations, such as oil extracts, decoction fil-
ter bags, and bags for inhalation through an authorised device. Medi-
cal use of cannabis is authorised in Italy and reimbursed within the
National Health System for selected medical conditions (as reported
in the Official Gazette no. 279 from 30 November 2015): (i) analgesia
in diseases involving spasticity associated with pain (multiple sclerosis,
spinal cord injury) resistant to conventional therapies; (ii) analgesia in
chronic pain (with particular reference to neurogenic pain) in which
treatment with nonsteroidal anti-inflammatory drugs or with cortisone
or opioid drugs has proved to be ineffective; (iii) anti-motion sickness
and antiemetic effect in nausea and vomiting, caused by chemother-
apy, radiotherapy, human immunodeficiency virus therapies, which
cannot be obtained with traditional treatments; (iv) appetite stimulat-
ing effect in cachexia, anorexia, loss of appetite in cancer patients or
patients with AIDS and in anorexia nervosa, which cannot be obtained
with standard treatments; (v) hypotensive effect in glaucoma resistant
to conventional therapies; (vi) reduction of involuntary body and facial
movements in Tourette syndrome, which cannot be achieved with
standard treatments.10-12
Spontaneous reports of suspected AEs to natural health products
(including galenic preparations containing herbals) are collected in Italy
within the Italian Phytovigilance system coordinated by the National
Institute of Health.13
In this context, the aim of the present study was to describe the
safety profile of cannabis for medical use, with a case-by-case analysis
of spontaneous reports of suspected AEs collected in Tuscany (Italy)
within the Italian Phytovigilance database.
2 | METHODS
We considered and evaluated all spontaneous reports of cannabis-
related suspected AEs collected within the Italian Phytovigilance data-
base (coordinated by the Italian National Institute of Health) since
2006 (date of cannabis for medical use approval) until December
2018. All reports associated with registered products or magistral
preparations containing cannabis were extracted from the database.
From the reporting form (available online at: http://www.epicentro.
What is already known about this subject
• Cannabis is a therapeutic option in multiple clinical condi-
tions, including chronic pain, AIDS, cancer, glaucoma,
Tourette syndrome and multiple sclerosis. Despite a sig-
nificant increase in medical cannabis use, its safety in clin-
ical practice is poorly characterised.
What this study adds
• This study shows that medical cannabis is generally well
tolerated and the majority of observed AEs are mild and
transient. Important safety issues for clinical practice
include the need for accurate prescription and monitoring
during the titration phase, particularly in presence of con-
comitant medications.
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iss.it/fitosorveglianza/pdf/scheda_fito.pdf), we collected all informa-
tion on: (i) patient's demographical (i.e. age, sex etc.) and clinical sta-
tus; (ii) AE, codified using the Medical Dictionary for Regulatory
Activities (MedDRA) classification, and described using the preferred
terms (PT) and system organ class (SOC) most frequently
reported14,15; (iii) AE degree of seriousness, classified according to the
World Health Organisation criteria as fatal, life-threatening, or requir-
ing hospitalisation of the patient, or causing serious/permanent dis-
ability, or causing congenital abnormalities, or other clinically relevant
conditions (https://apps.who.int/iris/bitstream/handle/10665/
67378/WHO_EDM_QSM_2002.2.pdf;jsessionid=EF4F54EFF6FBD63
4E21D2C075ADCA3C0?sequence=1; 29661234); (iv) AE outcome;
(v) ongoing cannabis therapy (i.e. product type, indication, dosage,
length of exposure, and administration route); (vi) concomitant
medications.
The causality assessment (categorised as certain, probable/likely,
possible, unlikely or unclassifiable) was performed using the World
Health Organisation–Uppsala Monitoring Centre system for
standardised case causality assessment (https://www.who.int/
medicines/areas/quality_safety/safety_efficacy/WHOcausality_
assessment.pdf).
Moreover, a multidisciplinary group of experts in pharmacology,
phytotherapy, clinical toxicology, pharmacovigilance and
phytovigilance fields performed a case-by-case clinical evaluation by,
with the aim of identifying potential factors (i.e. presence of drug–
drug interaction, DDI), which may have contributed to the AEs
collected.
Drug targets reported in the present manuscript conform to the
IUPHAR/BPS Guide to PHARMACOLOGY nomenclature
classification.16
Data a presented as number and percentages or, for continuous
variables, as mean and standard deviation (SD).
3 | RESULTS
During the study period (2006–2018), a total of 103 suspected AE
reports concerning medical cannabis use in Italy have been collected
in the Italian Phytovigilance database, of which 61 (59%) were
reported by Tuscany healthcare professionals. We have excluded
8 reports due to lacking information which did not allow us to perform
their clinical evaluation.
Table 1 and Table 2 show general patients' characteristics and a
case-by-case clinical description of the 53 evaluated reports, respec-
tively. The majority of patients were female (n = 41, 77.3%), with a
mean age of 61.9 (±SD, 15.9) years. Out of all reports evaluated,
39 (73.6%) were defined as nonserious and only in 2 cases AE serious-
ness was not specified. Most AE reports (n = 45, 84.9%) showed com-
plete resolution or improvement as AE outcome. Only 2 cases were still
unresolved at the time of AE reporting. Neuropathic pain and chronic
or nonspecified pain were the most reported indication for medical
cannabis use, amounting to 23 (43.4%) and 21 (39.6%) cases, respec-
tively. Indication for fibromyalgia and multiple sclerosis were reported
in 5 and 2 cases, respectively. Only 1 patient took his medication by
inhalation, while all other patients used cannabis orally, at a mean
dose of 138.5 (±SD, 139.0) mg per day. Length of exposure before AE
onset largely vary among cases, ranging from 1 day to 37 months
(mean 149.3 ± 242.4 days). Thirty-eight cases (71.7%) reported the
presence of concomitant medications, mainly represented by
pregabalin, gabapentin and other pain medication, such as para-
cetamol/codeine or oxycodone/naloxone fixed association.
Regarding the causality assessment, 46 (86.8%) and 5 (9.4%)
cases were judged as probably or possibly related to cannabis con-
sumption, respectively. Only 1 case was defined as certainly associ-
ated to cannabis administration, while for 1 case, information has not
TABLE 1 General patients' characteristics
Cases characteristics
No. of cases












Mean dose ± standard deviation, mg 138.5 ± 139.0










Not reported 2 (3.8)
Outcome
Complete resolution 36 (67.9)
Improvement 9 (17.0)
Still unresolved 2 (3.8)
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been sufficient to assess a causality relationship, thus, it has been
defined as not classifiable.
Overall, 53 AE reports referred to a total of 118 AEs, whose dis-
tribution is reported according to SOC classification (Figure 1). Fol-
lowing MedDRA hierarchy, the 5 most frequently reported SOC are:
psychiatric disorders (26.3%, n = 31 out of 118 AEs), followed by ner-
vous system disorders (22.0%, n = 26), ear and labyrinth disorders
(10.2%, n = 12), gastrointestinal disorders (10.2%, n = 12), general disor-
ders and administration site condition (8.5%, n = 10) and cardiac disor-
ders (8.5%, n = 10). Consequently, within each SOC the most
frequently reported PT were (see also Table 2): mental confusion, dys-
phoria, and anxiety (among psychiatric disorders); drowsiness and
lipothymia (among nervous system disorders); dizziness and balance dis-
orders (among ear and labyrinth disorders); nausea and vomiting
(among gastrointestinal disorders); lack of efficacy and dulling (among
general disorders and administration site condition); tachycardia and
tachyarrhythmia, and bradycardia (among cardiac disorders).
4 | DISCUSSION
Since 2006 (date of cannabis for medical use approval) until
December 2018, the Italian National Institute of Health collected
within its Phytovigilance database a total of 103 AE reports following
cannabis for medical use administration, mainly coming from Tuscany
(61 reports).17 The high number of AE reports collected in this Italian
region could be related to the well-established use of medical canna-
bis18 and to the clinicians' knowledge of AE reporting procedures.19
To the best of our knowledge this is the first case series study
describing all medical cannabis-related AEs observed in the general
population (all age groups).
Our study showed that cannabis treatment was not associated
with a high number of AEs, the majority of which were nonserious
and resolved completely without sequelae. Moreover, our results
were in line with those published in the study by Whiting and
colleagues,6 who found a statistically significant association between
cannabis use and the occurrence of dizziness, dry mouth, nausea,
fatigue, somnolence, euphoria, vomiting, diarrhoea, drowsiness, disori-
entation, confusion, loss of balance and hallucination. Moreover, in
their systematic review, a statistically significant association was
highlighted for the following SOCs: gastrointestinal, psychiatric and
nervous system disorders, general disorders and administration site
conditions, ear and labyrinth disorders, and renal and urinary disor-
ders.6 Following, the description of our case-by-case clinical evalua-
tion and the biological explanation of observed AEs, reported
according to the SOCs most frequently reported (Table 2).
4.1 | Psychiatric and nervous system disorders
Among people who use cannabis for recreational purposes, desired
psychotropic THC-related acute effects of mild euphoria, relaxation



























































































































































































































recreational use of cannabis, especially in naïve individuals, can cause
motor coordination and executive function impairment, anxiety, panic
attacks and psychotic episodes. Despite AEs of therapeutic cannabis
resemble to those experienced during the recreational use, there are
major differences both in terms of spectrum and intensity of these
effects.20
In our sample, psychiatric disorders include several AEs (reported
as PT), such as: mental confusion; depression and suicidal ideation;
anxiety; acute psychosis; body altered perception; and panic attacks.
In only 2 cases did patients report episodes of hallucinations. These
transient psychotic-like experiences are described in the literature21
and, differently to psychotic disorders, they resolve within a few
hours and rarely cause distress. A study published in 2004 and per-
formed on healthy volunteers underlines the occurrence of both posi-
tive (i.e. hallucinations, delusions, racing thoughts etc.) and negative
symptoms (i.e. apathy, lack of emotion, poor or nonexistent social
functioning etc.), similar to those experienced by schizophrenic
patients. Nevertheless, no serious AEs has occurred during this
study.21 Moreover, neurological or psychiatric AEs seems to increase
with higher THC concentrations, suggesting a potential relationship
between cannabis dosages and AEs seriousness,22 as in our case of
accidental overdose (case 2).
A systematic review has collected data from 11 studies on psy-
chosis highlighting an increased risk of psychotic outcome in individ-
uals who never used cannabis, and an increased risk of psychotic
outcome and depression in those who frequently used cannabis. Four
of the included studies reported an association between cannabis use
and increased risk of suicidal ideation, while the other 7 studies
emphasised an association with anxiety outcomes.23 Another system-
atic review of randomised controlled trials of medical cannabinoids
confirmed a significant higher rate in patients exposed to cannabis
both for nervous system and psychiatric disorders.24
The hypothesis of the association between the use of cannabi-
noids and the development of psychosis is still debated. Epidemiologi-
cal studies have consistently demonstrated that cannabis use is
associated with an increased risk of schizophrenia-like psychoses. This
risk varies according to the dose and duration of use, on top of age
use and genetic factors, including partially shared genetic predisposi-
tion with schizophrenia.25
Considering patients' average age in our sample, it is important
to note that cannabis-induced nervous system disorders are not
specific to older adults, even if, during clinical trials, sedation-like
symptoms such as drowsiness, tiredness and somnolence are more
reported in older subjects exposed to cannabis than in controls.26
Clinicians should always take these kind of AEs into account, par-
ticularly to better manage patients' adherence to cannabis prescrip-
tions. This aspect is also important because it has been found that
experiencing a cannabis-related AE (i.e. dizziness, fatigue, mild anxi-
ety and feeling “weird”) is more common among nonadhering
patients than among adhering ones.27 Thus, improving patients'
education on cannabis treatments, could improve their therapy
compliance, and reduce nonadherence affects, in particular psychi-
atric and nervous system AEs.
4.2 | Ear and labyrinth disorders
Among chronic users of cannabis, a decrease in maximum amplitude
on torsion swing and an increase in incidence of nystagmus in supine
positions have been observed since the 1970s.28 Following studies,
based on immunohistochemistry, demonstrate that CB1 and CB2
receptors are localised in the central nervous system and cover areas
involved in movement control (i.e. basal ganglia, cerebral cortex, and
cerebellum). Endocannabinoids are also involved in setting the base-
line activity of the spinal locomotor circuitry, where CB1 activation or
antagonism results in an increase and decrease of locomotor fre-
quency, respectively.29 Moreover, it has been demonstrated that CB1
receptors exist in significant densities in the vestibular nucleus com-
plex and are likely to contribute to the neurochemical control of ves-
tibular reflexes.30 Given that CB1 receptors have apparently an
exclusive presynaptic localisation, in the vestibular nucleus complex
F IGURE 1 Distribution of medical
cannabis-related adverse events
according to system organ classes
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they could be situated on presynaptic glutamatergic axon terminals
where they would reduce glutamate release during vestibular stimula-
tion.31 In this frame, the activation of these receptors could explain
the occurrence of loss of balance and labyrinth disorders as cannabis-
related AEs.30
In chronic users of cannabis, the cerebellum presents neuroana-
tomical alterations that impair its ability to execute postural adjust-
ments, resulting in trembling.32,33 Results from a study published in
2017 suggest that cannabis users show subtle changes in gait, primar-
ily in open-chain components of walking gait, but not in balance.34
The main clinical concern refers to cannabis use in older patients,
as those in our sample, who are notably susceptible to AEs due to
physiological changes, comorbidities, concurrent medication use and
cognitive impairment.35 Even if this assumption has not been already
confirmed, sedation-like neurological AEs of cannabis may expose the
elderly to an increased risk of falls. In this frame, a recent study exam-
ines the effect of THC on balance and gait in old demented adults
using cannabinoids. THC administration in elderly significantly
increases sway during standing and stride length and trunk sway dur-
ing walking.36 Another systematic review and meta-analysis included
7 randomised controlled trials that reported data about hearing AEs
after cannabis use. The combined risk for all hearing-related AEs has
been significantly higher among cannabis users compared to placebo-
exposed patients, with tinnitus, loud noise, ringing in the ears, and
vertigo as the most commonly reported AEs.37
4.3 | Gastrointestinal disorders
In our sample, gastrointestinal disorders include several AEs (reported
as PT), such as: nausea, vomiting, and gastritis. A systematic review
and meta-analysis published by Aviram and colleagues37 has collected
evidence on gastrointestinal AEs in patients treated with cannabis-
based medicines for chronic and postoperative pain management.
From 20 randomised controlled trials, the combined risk ratio for all
gastrointestinal AEs was significantly higher in patients exposed to
cannabinoids than in controls, especially in those who used
oromucosal and oral cannabis preparations.37 Furthermore, cannabis-
related nausea and vomiting appear to be THC-dose-dependent AEs:
at low doses, THC is characterised by antiemetic properties, but at
high doses, is proemetic.38
Despite antiemetic effects of cannabis are well described, as in
animal models cannabinoids show both an antiemetic/emetic
response,39 a paradoxical syndrome of hyperemesis resultant from
cannabinoids exposure has been already defined also in humans. This
syndrome is labelled cannabinoid hyperemesis syndrome (CHS), and
consists of nausea, vomiting and abdominal pain particularly associ-
ated with chronic use.40 A recent retrospective observational study
shows that, among cannabis users, gastrointestinal symptoms, includ-
ing CHS, are the most common cause of cannabis-related emergency
departments visits.41 Two main hypothesis involving THC try to
explain this phenomenon. The first suggests that THC directly acti-
vates cannabinoid receptors in the enteric nervous system, reducing
gastric motility, and promoting a proemetic state. A second explana-
tion of this phenomenon has taken into account (i) the impairing in
thermoregulation and (ii) the alteration of the hypothalamic–pitui-
tary–adrenal axis caused by cannabinoids, which reduces body tem-
perature and prolactin, gonadotropin, and growth hormone release,
and increases corticotrophin secretion.42 Impaired body temperature
and hypothalamic–pituitary–adrenal axis alterations have been also
associated with the development of CHS, which is characterised by
3 phases: prodromal, hyperemetic and recovery phase. Patients usu-
ally access emergency departments during the hyperemetic phase,
presenting profuse vomiting.43 Even if mild, nausea and vomiting
could have a deep impact on patients' morbidity and quality of life,
and an economic burden for hospitals and healthcare systems. There-
fore, clinicians should consider cannabis as a cause of cyclic nausea
and vomiting, especially in chronic cannabis users and in patients
treated with oral cannabis preparations, particularly in oncological
patients.
4.4 | General disorders and administration site
condition
In our sample, among general disorders and administration site condi-
tion, lack of efficacy is the most frequently reported PT. Such event
can derive from (i) the prescription of an inadequate dosage of pre-
scribed/administered cannabis, (ii) presence of interactions that can
reduce the effectiveness of the preparation, (iii) incorrect intake, or
(iv) personal sensitivity.
In 2015 the Italian Ministry of Health has recommended clinicians
to start a therapy based on cannabis with the minimum dose needed
and, if necessary, to increase the dosage gradually.44 Moreover, clini-
cians have to declare in their prescription which type of cannabis
should be used for the preparation, according to the proper level of
THC and CBD, and the total dose of cannabis should be adapted
according to patient's clinical characteristics (i.e. age, sex, weight,
comorbidity and presence of concomitant medications). Due to the
need for a titration phase and to the accumulation in adipose tissue,
until the circulating active fraction of THC and CBD raises, first
administrations may result ineffective.45 Of note, standard dosages
for cannabis are currently not available from guidelines. Evidences
provided by clinical trials allowed to establish the maximum daily
doses recommended in clinical practice that ranges, from an initial
dose of 25 mg to around 130 mg of cannabis with 19% of THC, both
for chronic pain and multiple sclerosis, respectively.46
In our sample we encountered a total of 5 cases of lack of efficacy,
and its onset differed among them. In particular, 3 patients (cases
5, 25 and 29) are affected by chronic neuropathic pain and 2 women
(cases 49 and 50) are affected by multiple sclerosis. All of them have
been treated with oral preparation of cannabis within the rec-
ommended therapeutic dose range. Moreover, in cases 29 and
49, patients were treated with cannabis concomitantly with other
drugs, in particular analgesics (paracetamol/acetylsalicylic
acid/caffeine and paracetamol/codeine fixed associations), etoricoxib,
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colchicine and warfarin. Since patients with multiple sclerosis (cases
49 and 50) have been treated with very low doses of cannabis (60 mg
daily) for a short period (1 and 2 months, respectively), we hypo-
thesise that their titration phase was still ongoing when the AE lack of
efficacy was reported. Considering that the length of medical cannabis
treatment was very heterogeneous among these patients, and given
the lack of information about individual factors, such as comorbidities,
concomitant treatment, and genetic factors, we were not able to eval-
uate the possible relationship between length of medical cannabis
exposure and the event lack of efficacy. Further investigations, with a
larger sample of patients, could be performed to better clarify this
issue. Moreover, to date no interaction between cannabinoids and
etoricoxib and colchicine has been clearly identified. However, given
that THC and CBD are both substrates and modulators of cytochrome
(CYP) P450,47 DDIs could not be excluded, particularly with drugs at
low therapeutic index as warfarin.48
4.5 | Cardiac disorders
In our sample, we also observed some cardiovascular (CV) AEs, in par-
ticular (reported as PT): bradyarrhythmia (case 14) and bradycardia
(case 46), tachycardia and tachyarrhythmia (cases 25, 33, 37, 40, and
48), supraventricular tachycardia (cases 16 and 44), and palpitations
(case 42).
Regarding CV AEs related to medical cannabis (e.g. atrial fibrilla-
tion, acute coronary syndromes, ventricular tachycardia, and even
sudden death), available evidence appears to be insufficient to draw a
definitive conclusion on the effects of cannabis on these kind of mani-
festations and its possible mechanism.49 It is well known that CB2
receptors are located in cardiac myocyte and in the smooth muscles
of blood vessels. Nevertheless, the exact mechanism of the various
vascular effect of cannabis is not yet clear.50 Furthermore, in the
study published by Whiting and colleagues, the authors did not find
any statistically significant association between cannabis use and the
occurrence of CV AEs.6
4.6 | Drug-drug interactions
In the majority of cases reported in our sample, patients are adminis-
tered with at least another concomitant prescribed medication over
their cannabis prescription. Although DDIs are a major concern for
physicians, few studies have examined the effects of DDIs involving
cannabis preparations. Most available evidence derives only from pre-
clinical studies and currently the extent of cannabis-related DDIs in
real-world practice remains poorly investigated.
As mentioned above, oral cannabinoids are metabolised by the
enzyme family of CYP450, and THC and CBD are inhibitors of
CYP2C9, CYP3A4, and CYP2C19, while smoked cannabis is demon-
strated to induce CYP1A1 and CYP1A2.51 Moreover, CBD inhibits P-
glycoprotein mediated transports in a dose-dependent manner.52
Established cannabis-related DDIs involve THC and psychotropic
agents,51 CBD and anticancer agents,53 CBD and gabapentin,54 and
cannabinoids and warfarin.48 In general, clinicians should always take
into account that medical cannabis could bidirectionally interact with
concomitant administered agents by affecting membrane transporters
and/or metabolising enzymes.47
In our sample, among patients treated with at least another pre-
scribed medication over cannabis, only in 1 case (case 48) did the phy-
sician specifically report pharmacological interaction as PT. However,
from our case-by-case analysis, we have identified other 16 cases in
which the presence of DDI could be involved in the AE. Alteration of
the mental status, dysphoria, dizziness, drowsiness and balance disor-
ders are reported concomitantly to the use of opioids, such as fenta-
nyl (cases 3 and 28), tapentadol (case 4), codeine (alone or in
association, cases 6, 9, 30 and 47), oxycodone and naloxone (cases
17, 21, 33 and 47), and concomitantly to the use of pregabalin (cases
2, 9, 17, 21, 28, 33, 38 and 40) and gabapentin (case 48). One patient
(case 21) has shown as concomitant medications alprazolam,
escitalopram, oxycodone and pregabalin, together with duloxetine,
insulin and pantoprazole. Furthermore, we observed a patient con-
comitantly exposed to cannabis and cyclosporine (case 53), after a
renal transplant, who experienced hallucinations and nausea. This case
is particularly relevant due to the fact that the concomitant exposure
to cannabis and cyclosporine could be related to a transplant failure.55
These results allow us to make some considerations. Considering
that the AEs reported in all these cases are common to cannabis and
opioid derivatives, benzodiazepines and antiepileptic agents, and that
are listed as adverse drug reactions in the summary of products char-
acteristics for all the concomitant medications registered, we believe
that all reported AEs may be due to a synergistic interaction between
cannabis and other agents. Moreover, in a clinically complex condition
such those represented by some of our cases and considering the
excellent analgesic properties of cannabis,4 it should be advisable to
gradually reduce the administration of opioids, up to interrupt it when
possible, in order to reduce the potential inappropriate prescription.
Finally, according to pharmacovigilance and phytovigilance
guidelines,56,57 the quite low number of DDIs identified and reported
in our sample, probably highlights the need to increase physicians'
awareness about this clinically relevant event as cannabis-related
cause of AEs.
5 | STRENGTHS AND LIMITATIONS
This study has some limitations and strengths. First, our analysis is
based on AE reports that are affected by limits that include inaccurate
and incomplete information, mainly related to lack of clinical data.
Given that, the absence of information that was not listed in AE
reports and that might have influenced the clinical evaluation of each
report (i.e. the lack of information on previous and/or current patient
medical conditions which could affect the clinical evaluation of each
case) could not always be excluded. Moreover, data concerning medi-
cal cannabis prescriptions in Tuscany among the study period were
not available.
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Despite these limitations, this is the first study describing all med-
ical cannabis-related AEs observed in the general population. Further-
more, considering that medical cannabis-related AEs reporting is
mandatory for clinicians, we can affirm that our case series includes
the totality of patients who experienced a cannabis-related AE in Tus-
cany within the study period.
6 | CONCLUSIONS
Our case-by-case assessment of AEs following medical cannabis treat-
ment underlined several potential safety issues of great importance
for clinical practice.
Cannabis was well tolerated and the majority of AEs were mild
and transient. Nevertheless, prescribing cannabis, clinicians should be
aware that, especially during the titration phase, cannabis could result
ineffective and that the occurrence of psychiatric and gastrointestinal
AEs, mainly paradoxical nausea and vomiting, may increase as canna-
bis dosages increase too fast and if cannabis is administered orally.
Moreover, clinicians should be aware of the possible occurrence of
cannabis-related AEs in older or complex patients, exposed to con-
comitant synergic medications, for whom phenomena can occur not
only of interaction, but also of inappropriate prescribing. Our results
have also highlighted that cannabis was used as adjunct treatment in
a relevant proportion of cases, particularly in pain management, thus
justifying the importance of monitoring prescriptions.
The risks associated with long-term use of medical cannabis
are still poorly characterised in published clinical trials and observa-
tional studies. A good vigilance of cannabis-related AEs may
improve our knowledge of cannabis safety profile, filling the gaps
of clinical studies. Moreover, these results could ameliorate current
clinical practice and lead to correct use of cannabis exploiting its
full potential.
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